文献速递淋巴瘤

CD19 CAR-T细胞疗法在复发/难治性侵袭性B细胞淋巴瘤中的疗效与安全性:JULIET、ZUMA-1和TRANSCEND试验的观察

Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials.
PubMed 文献 · Am J Hematol · 2021-08-13

本文综述了axicabtagene ciloleucel、tisagenlecleucel和lisocabtagene maraleucel三种CD19 CAR-T产品在复发/难治性侵袭性B细胞淋巴瘤中的关键临床试验设计与结果,并讨论了真实世界患者特征对疗效和安全性的影响,以及输注后管理和未来试验方向。

要点

  • 三种CD19 CAR-T产品在制造、关键试验设计和数据报告上存在差异。
  • 真实世界数据可验证患者特征对axicabtagene ciloleucel和tisagenlecleucel疗效与安全性的影响。
  • CAR-T后管理需监测持续缓解和潜在长期副作用。

核心结论

  • CD19 CAR-T细胞疗法改善了复发/难治性侵袭性B细胞淋巴瘤患者的结局。
  • 不同CAR-T产品在制造、试验设计和数据报告上存在差异。
  • 真实世界数据有助于验证患者特征对疗效和安全性的影响。

研究设计与样本

  • 综述类文章,检索范围未明确报告。

主要发现

  • axicabtagene ciloleucel和tisagenlecleucel于2017年获批用于≥2线治疗后复发/难治的高级别B细胞淋巴瘤或DLBCL。
  • lisocabtagene maraleucel于2021年获批。
  • 早期商业使用报告提供了真实世界验证患者特征影响的机会。

临床怎么用

  • CAR-T治疗后需监测持续缓解和潜在长期副作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor (CAR)-T cell therapies have improved the outcome for many patients with relapsed or refractory aggressive B-cell lymphomas. In 2017, axicabtagene ciloleucel and soon after tisagenlecleucel became the first approved CAR-T cell products for patients with high-grade B-cell lymphomas or diffuse large B-cell lymphoma (DLBCL) who are relapsed or refractory to ≥ 2 prior lines of therapy; lisocabtagene maraleucel was approved in 2021. Safety and efficacy outcomes from the pivotal trials of each CAR-T cell therapy have been reported. Despite addressing a common unmet need in the large B-cell lymphoma population and utilizing similar CAR technologies, there are differences between CAR-T cell products in manufacturing, pivotal clinical trial designs, and data reporting. Early reports of commercial use of axicabtagene ciloleucel and tisagenlecleucel provide the first opportunities to validate the impact of patient characteristics on the efficacy and safety of these CAR-T cell therapies in the real world. Going forward, caring for patients after CAR-T cell therapy will require strategies to monitor patients for sustained responses and potential long-term side effects. In this review, product attributes, protocol designs, and clinical outcomes of the key clinical trials are presented. We discuss recent data on patient characteristics, efficacy, and safety of patients treated with axicabtagene ciloleucel or tisagenlecleucel in the real world. Finally, we discuss postinfusion management and preview upcoming clinical trials of CAR-T cell therapies.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Westin JR, Kersten MJ, Salles G, et al. Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials. Am J Hematol. 2021. PMID: 34310745. doi:10.1002/ajh.26301

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。